Evidence map›Paper›PMID 22850893›Full record

ArticleBreast cancer research and treatment2012

Transcriptional activation of breast cancer-associated gene 2 by estrogen receptor.

Fathima R Kona, Karri Stark, Luke Bisoski, Daniela Buac, Qiuzhi Cui, Q Ping Dou

Abstract read
In one paragraph

Article in Breast cancer research and treatment, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Fathima R KonaBarbara Ann Karmanos Cancer Institute and Departments of Oncology, Pharmacology and Pathology, School of Medicine, Wayne State University, 540.1 Hudson Webber Cancer Research Building, Mail Code HW05AO, 4100 John R Road, Detroit, MI 48201-2013, USA.
Karri Stark
Luke Bisoski
Daniela Buac
Qiuzhi Cui
Q Ping Dou
The Barbara Ann Karmanos Cancer Institute · USWayne State University · US

Funding

Tumor Biology and Microenvironment (Program 1)P30CA022453 · NCI · WAYNE STATE UNIVERSITY · PI PAUL M STEMMER · 1985 to 2026
$68.4M
Roles of polymorphic COMT, tea polyphenols and proteasome in cancer preventionR01CA120009 · NCI · WAYNE STATE UNIVERSITY · PI DOU, QING PING · 2006 to 2010
$1.5M
The BCA2 Ubiquitin E3 Ligase as a Target in Breast CancerR01CA127258 · NCI · WAYNE STATE UNIVERSITY · PI DOU, QING PING · 2007 to 2011
$1.2M
NCI NIH HHS 1R01CA120009NCI NIH HHS 3R01CA120009-04S1NCI NIH HHS 5R01CA127258-05NCI NIH HHS P30 CA022453NCI NIH HHS R01 CA120009NCI NIH HHS R01 CA127258
6 · The paper itself

Abstract

RNF115, or Breast Cancer-Associated Gene 2 (BCA2), encodes a RING-finger ubiquitin E3 ligase, expression of which was associated with estrogen receptor (ER)-positive status in human breast tumors. Although the BCA2 promoter contains several estrogen response element (ERE) half-sites, the role of ER in the regulation of BCA2 transcription has not been reported. The aim of this study is to investigate the molecular mechanism by which estrogen regulates BCA2 transcription. BCA2 mRNA and protein levels were examined by RT-PCR and Western blot analysis, respectively, and localization was assessed by immunofluorescence. BCA2 promoter activity in response to E(2) was tested by a dual luciferase reporter assay and ER binding to the BCA2 promoter was examined by chromatin immunoprecipitation assay. We found that BCA2 mRNA and protein levels are regulated by estrogen in ER-positive MCF7 breast cancer cells and MDA MB 231 cells stably transfected with ER. Estrogen treatment in hormonal depleted MCF7 and MDA MB 231/ER stably transfected cells resulted in increased nuclear ER and cytoplasmic and nuclear BCA2 staining. Cycloheximide is not able to inhibit BCA2 mRNA levels, suggesting potential BCA2 regulation at the transcriptional level. Anti-estrogens like tamoxifen and ICI 182 178 counteracted E(2)-induced BCA2 protein and knockdown of ER by ER siRNA resulted in a significant decrease in BCA2 protein and a lower nuclear expression pattern. Estrogen treatment lead to a significant increase in BCA2 promoter response, associated with increased binding of ER to the ERE region of the BCA2 promoter. BCA2 is therefore a newly identified transcriptional target of estrogen receptor.

Indexed as

Gene Expression Regulation, NeoplasticTranscriptional ActivationBreast NeoplasmsChromatin ImmunoprecipitationCycloheximideEstradiolEstrogen Receptor alphaEstrogen Receptor ModulatorsFemaleGene Knockdown TechniquesGenes, ReporterHumansLuciferases, RenillaMCF-7 CellsProtein BindingProtein Synthesis InhibitorsCycloheximideESR1 protein, humanEstradiolEstrogen Receptor alphaEstrogen Receptor ModulatorsLuciferases, RenillaProtein Synthesis InhibitorsRNF115 protein, humanUbiquitin-Protein Ligases

Identifiers

PMID22850893
PMCPMC3759292
OpenAlexW2022126275

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.